These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 606428)

  • 1. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone histomorphometry in patients with chronic renal failure: effect of 1alpha-hydroxyvitamin D3.
    Melsen F; Nielsen HE; Christensen MS
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():39s-44s. PubMed ID: 606423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
    Pietrek J; Kokot F; Kuska J
    Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
    [No Abstract]   [Full Text] [Related]  

  • 8. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 9. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia.
    Peacock M; Aaron JE; Heyburn PJ; Nordin BE
    Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.
    Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH
    Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of vitamin D resistant hypophosphataemic osteomalacia with 1alpha-hydroxy vitamin D3.
    Peacock M; Heyburn PJ; Aaron JE
    Calcif Tissue Res; 1977 May; 22 Suppl():55-62. PubMed ID: 912585
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 18. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.